Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 56

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 56
---
. Endicott met in person, and
Mr. Frinzi conveyed that, based on his discussions with the members of the Board, STAAR would continue working to execute its standalone business plan.

On April 26, 2024, Mr. Endicott sent Mr. Frinzi a letter expressing disappointment in STAAR’s response, and reiterated
his request to engage with STAAR.

On April 30, 2024, the Board met to discuss the April Offer as well as the current market
landscape and STAAR’s historical and potential future performance. The Board considered, among other things, an overview of fiduciary duty considerations under Delaware law provided by Nathaniel Sisitsky, who was then serving as STAAR’s
General Counsel and Corporate Secretary, and who currently serves as STAAR’s Chief Legal Officer and Corporate Secretary. After discussion, the Board confirmed its view that, based on its current financial position and outlook, as well as the
importance of continued execution without distraction, STAAR should continue to pursue its standalone business plan rather than engaging with Alcon, but decided to obtain the perspective of an independent financial adviser for consideration at the
next regular meeting of the Board. Mr. Frinzi subsequently conveyed the Board’s decision regarding the April Offer to Mr. Endicott.

At its June 20, 2024 meeting, the Board continued its review of the business plan and strategy of STAAR, including the opportunities and
risks associated therewith. Members of STAAR’s management and representatives of Citi, STAAR’s financial advisor, provided an update on the medical technology and ophthalmology markets as well as expectations for M&A activity in the
medical technology and ophthalmology markets, and potential strategic transactions involving STAAR. The Board also reviewed STAAR’s performance to date, including its strong performance in recently completed fiscal quarter, and the expected
performance in the second half of STAAR’s fiscal year, including in China and other countries in which STAAR operated, and potential opportunities and risks related thereto. The Board discussed, among other things, the importance of realizing
a strong period of sales in China during the typical high season.

From June 2024 through October 2024, STAAR continued to execute on its
standalone business plan, including its expansion into additional geographic markets and increased marketing efforts in its existing geographic markets. During this period, STAAR’s business in its largest market, China, faced a greater than
expected economic slowdown and